Počet záznamů: 1
Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
- 1.
SYSNO ASEP 0533049 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism Tvůrce(i) Smolková, Katarína (FGU-C) RID, ORCID, SAI
Mikó, E. (HU)
Kovács, T. (HU)
Leguina-Ruzzi, Alberto A. (FGU-C) RID, ORCID
Sipos, A. (HU)
Bai, P. (HU)Zdroj.dok. Antioxidants & Redox Signaling. - : Mary Ann Liebert - ISSN 1523-0864
Roč. 33, č. 13 (2020), s. 966-997Poč.str. 32 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova NRF2 ; cancer ; cancer metabolism ; reactive species Vědní obor RIV CE - Biochemie Obor OECD Biochemistry and molecular biology CEP NV19-01-00101 GA MZd - Ministerstvo zdravotnictví Způsob publikování Open access Institucionální podpora FGU-C - RVO:67985823 UT WOS 000525301800001 EID SCOPUS 85086841484 DOI https://doi.org/10.1089/ars.2020.8024 Anotace Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent.
Critical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system.
Future Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.
Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2021 Elektronická adresa https://www.liebertpub.com/doi/10.1089/ars.2020.8024
Počet záznamů: 1